Analysis of 136 febrile neutropenic episodes in children with cancer: Evaluation of treatment effectiveness and cost

Pediatric Hematology and Oncology

Volumn 21, Issue 6, 2004, Pages 535-543

  Çorapçioǧlu, Funda ^a,b   Sarialioǧlu, Faik ^a   Olgun, Nur ^a   Uysal, Kamer Mutafoǧlu ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Cumhuriyet Mah   (Turkey)

Author keywords

Cancer; Children; Cost; Febrile neutropenia

Indexed keywords

ACICLOVIR; AMIKACIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CARBAPENEM; CEFEPIME; FLUCONAZOLE; GLYCOPEPTIDE; HEMOPOIETIC GROWTH FACTOR; MEROPENEM; METRONIDAZOLE; PIPERACILLIN; SULTAMICILLIN; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; CHILD; CHILD HOSPITALIZATION; CHILDHOOD CANCER; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HOSPITAL DISCHARGE; HUMAN; INFANT; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDICAL DOCUMENTATION; MONOTHERAPY; NEUTROPENIA; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HEALTH CARE COSTS; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA;

EID: 4444345434     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490477347     Document Type: Article

References (25)

1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
2. Chanock SJ, Piazzo PA. Fever in the neutropenic host. Infect Dis Clin North Am. 1996;10:777-796.
3. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol. 2000;27:335-346.
4. Klastersky J. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. Curr Opin Oncol. 1998;10:284-290.
5. Freifeld AG, Wlash TJ, Pizzo PA. Infectious complications in the pediatric cancer patient. In: Pizzo PA, Poplack DG, eds. Principles and Practise of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997:1069-1114.
6. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
7. Pizzo PA. Evaluation of fever in the patients with cancer. Eur J Cancer. 1989;25:9-16.
8. Hann I, Viscoli C, Paesmans M, et al. A comprasion of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Hematol. 1997;99:580-588.
9. Viscoli C, Castagnola C. Planned progressive antimicrobial therapy in neutropenic patients. Br J Hematol. 1998;102:879-888.
10. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381-396.
11. Gaya H. Empirical therapy of infections in neutropenic patients. Br J Hematol. 1996;101:5-9.
12. Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother. 2000;44:3264-3271.
13. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative. Clin Infect Dis. 1999;29:508-514.
14. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29:503-507.
15. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988;108:30-35.
16. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-1272.
17. Aǧaoglu L, Devecioǧlu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001;13:281-287.
18. Mullen CA, Petropoulos D, Roberts WM, et al. Economic and resource utilization analysis of out-patient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol. 1999;21:212-218.
19. Rosenman M, Madsen K, Hui S, et al. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol. 2002;24:263-268.
20. Leese B, Collin R, Clark DJ. The cost of treating febrile neutropenia in patient with malignant blood disorders. Pharmacoeconomic. 1994;6:233-239.
21. Dranitsaris G, Tran TM, McGeer A, et al. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics. 1995;7:49-62.
22. Rahiala J, Perkkio M, Riikonen P. Prospective and randomized comprasion of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol. 1999;32:326-330.
23. Ayan I, Kebudi R, Dogan S, et al. Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy. Pediatr Hematol Oncol. 1996;13:417-424.
24. Pinkala UMS, Lanning M, Perkkiö M, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblactic leukemia in children. Med Pediatr Oncol. 2000;34:319-327.
25. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957-1960.